Oncology Clinical Pathways Spotlight
This week in health care trends, our oncology clinical pathways spotlight includes oncologists’ frustration with pathways, financial incentives for pathway adherence, and the NCCN Policy Summit.
The articles below are from our dedicated Oncology Clinical Pathways e-magazine. Follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)
When it comes to different pathways programs, oncologist John Hennessey says doctors are burdened by having to coordinate between multiple pathways: “It is a big issue. Practices are not saying we don’t want any pathways, but could we just have 1? Could it be the same? In particular, when you get into this generic versus that generic, it gets to the transactional level. It doesn’t make a lot of sense for non-payment if you pick the wrong sets of generics. The outcomes are the same, the costs are about the same. It’s just becoming burdensome.”
In this interview, Anthem’s Staff Vice President for Clinical Strategy Jennifer Malin, MD, describes how the insurer is “using payment reform, data-sharing, and a “we’re all in this together” attitude to encourage oncologists to improve the quality and lower the cost of the care they provide” — including offering “a financial incentive to encourage the use of cancer care pathways.”
Recently in Washington, D.C., NCCN held a policy summit to discuss “the impact of access on the treatment of cancer,” including bundled payments, narrow networks, employers and the ACA, and public versus private exchanges.